# KEYNOTE-189 (NCT03950674)

> Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)-Japan Extension Study

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03950674
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Non-Small-Cell Lung Carcinoma
- Interventions: Pembrolizumab 200 mg; Cisplatin; Carboplatin; Pemetrexed; Folic acid 350-1000 μg; Vitamin B12 1000 μg; Dexamethasone 4 mg; Saline solution
- Enrollment: 40
- Primary outcome: Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Blinded Central Imaging
- Primary outcome: Overall Survival (OS)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- Podcasts: 53
- YouTube: 50
- X threads: 22

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=keynote-189-nct03950674

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03950674", "email": "<work email>"}; the inbox owner confirms by the emailed link.